{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:26:54Z","timestamp":1792240014095,"version":"4.4.0"},"reference-count":233,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["SP\/11\/4\/29251"],"award-info":[{"award-number":["SP\/11\/4\/29251"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vitamin K antagonists (VKA) have long been the default drugs for anticoagulant management in venous thrombosis. While efficacious, they are difficult to use due to interpatient dose\u2013response variability and the risks of bleeding. The approval of fondaparinux, a heparin-derived factor Xa (fXa) inhibitor, provided validation for the development of direct oral anticoagulants (DOAC), and currently such inhibitors of thrombin and fXa are in clinical use. These agents can be used without regular coagulation monitoring, but the inherent risk of bleeding complications associated with blocking the common coagulation pathway remains. Efforts are now underway to develop DOACs that inhibit components of the intrinsic and extrinsic coagulation cascades upstream of thrombin and fX. Evidence from humans and from transgenic animal models suggests that this strategy may provide a better therapeutic margin between antithrombotic and antihemostatic effects. Here the design of active-site inhibitors of S1A proteases involved in coagulation and fibrinolysis is summarized.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.7b00772","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T16:50:07Z","timestamp":1509036607000},"page":"3799-3822","source":"Crossref","is-referenced-by-count":28,"title":["Design of Small-Molecule\nActive-Site Inhibitors of the S1A Family Proteases as Procoagulant\nand Anticoagulant Drugs"],"prefix":"10.1021","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5866-9271","authenticated-orcid":true,"given":"Peter M.","family":"Fischer","sequence":"first","affiliation":[{"name":"University of Nottingham , , ,","place":["Nottingham, U.K., NG7 2RD"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"2026090305371585700_cit1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0192623310389474","article-title":"Current\nunderstanding of hemostasis","volume":"39","author":"Gale","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"2026090305371585700_cit2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular\neffector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"2026090305371585700_cit3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/TA.0000000000000341","article-title":"Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis\nshutdown: The spectrum of postinjury fibrinolysis and relevance to\nantifibrinolytic therapy","volume":"77","author":"Moore","year":"2014","journal-title":"J. Trauma Acute Care\nSurg."},{"key":"2026090305371585700_cit4","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1111\/jth.13145","article-title":"Spatiotemporal regulation of coagulation and platelet\nactivation during the hemostatic response in vivo","volume":"13","author":"Ivanciu","year":"2015","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12872-015-0124-z","article-title":"Endothelial cell control of thrombosis","volume":"15","author":"Yau","year":"2015","journal-title":"BMC Cardiovasc. Disord."},{"key":"2026090305371585700_cit6","doi-asserted-by":"publisher","first-page":"18s","DOI":"10.1378\/chest.124.3_suppl.18S","article-title":"Thrombin\nand platelet activation","volume":"124","author":"Brass","year":"2003","journal-title":"Chest"},{"key":"2026090305371585700_cit7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.thromres.2011.11.040","article-title":"Factor XIII, clot structure, thrombosis","volume":"129","author":"Bagoly","year":"2012","journal-title":"Thromb. Res."},{"key":"2026090305371585700_cit8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fcimb.2014.00128","article-title":"The role of\ncoagulation\/fibrinolysis during Streptococcus pyogenes infection","volume":"4","author":"Loof","year":"2014","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"2026090305371585700_cit9","doi-asserted-by":"publisher","first-page":"W597","DOI":"10.1093\/nar\/gkt376","article-title":"Analysis tool web services from the EMBL-EBI","volume":"41","author":"McWilliam","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"2026090305371585700_cit10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/202498a0","article-title":"An enzyme\ncascade in the blood clotting mechanism, and its function as a biochemical\namplifier","volume":"202","author":"Macfarlane","year":"1964","journal-title":"Nature"},{"key":"2026090305371585700_cit11","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1126\/science.145.3638.1310","article-title":"Waterfall sequence\nfor intrinsic blood clotting","volume":"145","author":"Davie","year":"1964","journal-title":"Science"},{"key":"2026090305371585700_cit12","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/PAT.0b013e32834bf5f4","article-title":"Laboratory\ntesting of anticoagulants: the present and the future","volume":"43","author":"Favaloro","year":"2011","journal-title":"Pathology"},{"key":"2026090305371585700_cit13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jth.13194","article-title":"The contact activation and kallikrein\/kinin systems:\npathophysiologic and physiologic activities","volume":"14","author":"Schmaier","year":"2016","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fmed.2017.00019","article-title":"Factors XI and XII as targets for new anticoagulants","volume":"4","author":"Weitz","year":"2017","journal-title":"Front. Med."},{"key":"2026090305371585700_cit15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/joim.12430","article-title":"Factor XII:\na novel target for safe prevention of thrombosis and inflammation","volume":"278","author":"Kenne","year":"2015","journal-title":"J. Intern. Med."},{"key":"2026090305371585700_cit16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.biomaterials.2012.09.034","article-title":"A comparison of blood factor XII autoactivation in\nbuffer, protein cocktail, serum, and plasma solutions","volume":"34","author":"Golas","year":"2013","journal-title":"Biomaterials"},{"key":"2026090305371585700_cit17","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/jth.13383","article-title":"Factor XII: form determines\nfunction","volume":"14","author":"de Maat","year":"2016","journal-title":"J. Thromb. Haemostasis"},{"issue":"Suppl. 1","key":"2026090305371585700_cit18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/jth.12220","article-title":"Systems biology of coagulation","volume":"11","author":"Diamond","year":"2013","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit19","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1161\/01.ATV.0000168421.13467.82","article-title":"Regulation\nof blood coagulation by the protein C anticoagulant pathway","volume":"25","author":"Dahlba\u0308ck","year":"2005","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"key":"2026090305371585700_cit20","doi-asserted-by":"publisher","first-page":"S200","DOI":"10.1111\/jth.12897","article-title":"New insights into\nthe biology of tissue factor pathway inhibitor","volume":"13","author":"Maroney","year":"2015","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/00001721-200212000-00001","article-title":"Antithrombin:\na new look at the actions of a serine protease inhibitor","volume":"13","author":"Roemisch","year":"2002","journal-title":"Blood Coagulation Fibrinolysis"},{"key":"2026090305371585700_cit22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and\nthe control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev."},{"key":"2026090305371585700_cit23","doi-asserted-by":"publisher","first-page":"D503","DOI":"10.1093\/nar\/gkt953","article-title":"MEROPS: the database of proteolytic enzymes, their\nsubstrates and inhibitors","volume":"42","author":"Rawlings","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"2026090305371585700_cit24","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1021\/cr000033x","article-title":"Serine protease mechanism and specificity","volume":"102","author":"Hedstrom","year":"2002","journal-title":"Chem. Rev."},{"key":"2026090305371585700_cit25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1042\/bse0380095","article-title":"Proteases in blood clotting","volume":"38","author":"Walsh","year":"2002","journal-title":"Essays Biochem."},{"key":"2026090305371585700_cit26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/hae.12615","article-title":"Novel therapeutic approaches for haemophilia","volume":"21","author":"Shetty","year":"2015","journal-title":"Haemophilia"},{"key":"2026090305371585700_cit27","doi-asserted-by":"publisher","first-page":"8868","DOI":"10.1021\/acs.jmedchem.5b01128","article-title":"Design of specific serine protease inhibitors based\non a versatile peptide scaffold: conversion of a urokinase inhibitor\nto a plasma kallikrein inhibitor","volume":"58","author":"Xu","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit28","doi-asserted-by":"publisher","first-page":"9238","DOI":"10.1021\/acs.jmedchem.5b01171","article-title":"Discovery and SAR of novel and selective inhibitors\nof urokinase plasminogen activator (uPA) with an imidazo[1,2-a]pyridine scaffold","volume":"58","author":"Gladysz","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/978160805161811001010055","article-title":"Inhibitors\nof the plasminogen activation system - promising new agents for suppressing\nbreast cancer metastasis","volume":"1","author":"Tyndall","year":"2010","journal-title":"Front. Anti-Cancer\nDrug Discovery"},{"key":"2026090305371585700_cit30","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/0006-291X(68)90326-4","article-title":"On the active site of proteases. 3. Mapping the active\nsite of papain; specific peptide inhibitors of papain","volume":"32","author":"Schechter","year":"1968","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2026090305371585700_cit31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1074-5521(00)00104-6","article-title":"Structural basis for\nselectivity of a small molecule, S1-binding, submicromolar inhibitor\nof urokinase-type plasminogen activator","volume":"7","author":"Katz","year":"2000","journal-title":"Chem.\nBiol."},{"key":"2026090305371585700_cit32","doi-asserted-by":"publisher","first-page":"31842","DOI":"10.1074\/jbc.M401756200","article-title":"Molecular dissection\nof Na+ binding to thrombin","volume":"279","author":"Pineda","year":"2004","journal-title":"J. Biol.\nChem."},{"key":"2026090305371585700_cit33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1021\/acs.jpcb.5b10637","article-title":"Quantitative correlation\nof conformational binding enthalpy with substrate specificity of serine\nproteases","volume":"120","author":"Waldner","year":"2016","journal-title":"J. Phys. Chem. B"},{"key":"2026090305371585700_cit34","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1073\/pnas.0710894105","article-title":"Structural identification of the pathway of long-range\ncommunication in an allosteric enzyme","volume":"105","author":"Gandhi","year":"2008","journal-title":"Proc.\nNatl. Acad. Sci. U. S. A."},{"key":"2026090305371585700_cit35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bpc.2013.09.003","article-title":"Essential role of conformational\nselection in ligand binding","volume":"186","author":"Vogt","year":"2014","journal-title":"Biophys. Chem."},{"key":"2026090305371585700_cit36","doi-asserted-by":"publisher","first-page":"e120S","DOI":"10.1378\/chest.11-2294","article-title":"New antithrombotic drugs: antithrombotic therapy and\nprevention of thrombosis, 9th ed: American College of Chest Physicians\nevidence-based clinical practice guidelines","volume":"141","author":"Weitz","year":"2012","journal-title":"Chest"},{"key":"2026090305371585700_cit37","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0167-6296(97)00004-0","article-title":"Understanding DALYs (disability-adjusted life years)","volume":"16","author":"Murray","year":"1997","journal-title":"J. Health Econ."},{"key":"2026090305371585700_cit38","unstructured":"http:\/\/www.who.int\/healthinfo\/global_burden_disease\/2004_report_update\/en\/index.html (accessed August 9, 2017)."},{"key":"2026090305371585700_cit39","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence,\nand years lived with disability for 301 acute and chronic diseases\nand injuries in 188 countries, 1990\u20132013: a systematic analysis\nfor the Global Burden of Disease Study 2013","volume":"386","author":"Global Burden of Disease Study 2013 Collaborators.","year":"2015","journal-title":"Lancet"},{"key":"2026090305371585700_cit40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00129784-200808010-00003","article-title":"Low-molecular-weight heparins: mechanisms, trials,\nand role in contemporary interventional medicine","volume":"8","author":"Canales","year":"2008","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"2026090305371585700_cit41","doi-asserted-by":"publisher","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management\nof the vitamin K antagonists: American College of Chest Physicians\nevidence-based clinical practice guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"2026090305371585700_cit42","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1001\/archinte.164.19.2176","article-title":"International normalized ratio increase\nbefore warfarin-associated hemorrhage - Brief and subtle","volume":"164","author":"Kucher","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"2026090305371585700_cit43","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.thromres.2004.11.025","article-title":"Optimal INR for\nprevention of stroke and death in atrial fibrillation: a critical\nappraisal","volume":"117","author":"Oden","year":"2006","journal-title":"Thromb. Res."},{"key":"2026090305371585700_cit44","doi-asserted-by":"publisher","first-page":"29387","DOI":"10.1038\/srep29387","article-title":"A novel,\nrapid method to compare the therapeutic windows of oral anticoagulants\nusing the Hill coefficient","volume":"6","author":"Chang","year":"2016","journal-title":"Sci. Rep."},{"key":"2026090305371585700_cit45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4137\/CMBD.S5118","article-title":"Safety and\nefficacy of argatroban in the management of heparin-induced thrombocytopenia","volume":"4","author":"Saugel","year":"2011","journal-title":"Clin. Med. Insights: Blood Disord."},{"key":"2026090305371585700_cit46","doi-asserted-by":"publisher","first-page":"9S","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics,\nand pharmacodynamics of dabigatran etexilate, an oral direct thrombin\ninhibitor","volume":"15","author":"Stangier","year":"2009","journal-title":"Clin. Appl. Thromb.\/Hemostasis"},{"key":"2026090305371585700_cit47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of\nrivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026090305371585700_cit48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11239-009-0421-4","article-title":"Apixaban: an emerging oral factor Xa inhibitor","volume":"29","author":"Roser-Jones","year":"2010","journal-title":"J. Thromb. Thrombolysis"},{"key":"2026090305371585700_cit49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/17512433.2016.1258301","article-title":"The factor\nXa inhibitor edoxaban for the prevention of stroke and systemic embolism\nin patients with atrial fibrillation","volume":"10","author":"Minguet","year":"2017","journal-title":"Expert\nRev. Clin. Pharmacol."},{"key":"2026090305371585700_cit50","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1160\/TH09-09-0659","article-title":"Comparative efficacy and safety of the novel oral anticoagulants\ndabigatran, rivaroxaban and apixaban in preclinical and clinical development","volume":"103","author":"Ufer","year":"2010","journal-title":"Thromb. Haemostasis"},{"key":"2026090305371585700_cit51","doi-asserted-by":"publisher","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran,\nrivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"2026090305371585700_cit52","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.jcin.2014.06.014","article-title":"Direct oral anticoagulants.\nNew drugs and new concepts","volume":"7","author":"Levy","year":"2014","journal-title":"JACC: Cardiovasc.\nInterventions"},{"key":"2026090305371585700_cit53","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the\nefficacy and safety of new oral anticoagulants with warfarin in patients\nwith atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2026090305371585700_cit54","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/14779072.2016.1224179","article-title":"Upstream versus downstream\nthrombin inhibition","volume":"14","author":"Gulpen","year":"2016","journal-title":"Expert Rev. Cardiovasc.\nTher."},{"key":"2026090305371585700_cit55","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/jth.13005","article-title":"Factor XI and contact activation\nas targets for antithrombotic therapy","volume":"13","author":"Gailani","year":"2015","journal-title":"J. Thromb.\nHaemostasis"},{"key":"2026090305371585700_cit56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0049-3848(96)00111-9","article-title":"Fibrinogen and fibrin\n- proteins with complex roles in hemostasis and thrombosis","volume":"83","author":"Blomba\u0308ck","year":"1996","journal-title":"Thromb. Res."},{"key":"2026090305371585700_cit57","doi-asserted-by":"publisher","first-page":"7597","DOI":"10.1073\/pnas.95.13.7597","article-title":"Prothrombin deficiency results in embryonic and neonatal\nlethality in mice","volume":"95","author":"Sun","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.\nS. A."},{"key":"2026090305371585700_cit58","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1055\/s-0037-1613344","article-title":"Rescue of prothrombin-deficiency\nby transgene expression in mice","volume":"88","author":"Sun","year":"2002","journal-title":"Thromb. Haemostasis"},{"key":"2026090305371585700_cit59","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/j.1365-2516.2008.01832.x","article-title":"Abnormalities of\nprothrombin: a review of the pathophysiology, diagnosis, and treatment","volume":"14","author":"Meeks","year":"2008","journal-title":"Haemophilia"},{"key":"2026090305371585700_cit60","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1074\/jbc.M411606200","article-title":"Crystal\nstructure of thrombin bound to heparin","volume":"280","author":"Carter","year":"2005","journal-title":"J. Biol.\nChem."},{"key":"2026090305371585700_cit61","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1021\/bi0525369","article-title":"Structural basis for sequential cleavage of fibrinopeptides\nupon fibrin assembly","volume":"45","author":"Pechik","year":"2006","journal-title":"Biochemistry"},{"key":"2026090305371585700_cit62","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/35006683","article-title":"Structural basis for the anticoagulant\nactivity of the thrombin-thrombomodulin complex","volume":"404","author":"Fuentes-Prior","year":"2000","journal-title":"Nature"},{"key":"2026090305371585700_cit63","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/jth.13171","article-title":"Discovery and characterization of\nan antibody directed against exosite I of thrombin","volume":"14","author":"Baglin","year":"2016","journal-title":"J. Thromb. Haemostasis"},{"issue":"Suppl. 3","key":"2026090305371585700_cit64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000069104","article-title":"Historical\nperspective of the development of thrombin inhibitors","volume":"32","author":"Markwardt","year":"2002","journal-title":"Pathophysiol. Haemostasis Thromb."},{"key":"2026090305371585700_cit65","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/0049-3848(79)90014-8","article-title":"D-Phe-Pro-Arg-CH2Cl - A selective affinity label for thrombin","volume":"14","author":"Kettner","year":"1979","journal-title":"Thromb. Res."},{"key":"2026090305371585700_cit66","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1002\/j.1460-2075.1989.tb08511.x","article-title":"The refined 1.9 \u00c5 crystal-structure\nof human alpha-thrombin:  interaction with D-Phe-Pro-Arg chloromethylketone\nand significance of the Tyr-Pro-Pro-Trp insertion segment","volume":"8","author":"Bode","year":"1989","journal-title":"EMBO J."},{"key":"2026090305371585700_cit67","doi-asserted-by":"crossref","first-page":"20085","DOI":"10.1016\/S0021-9258(18)54894-8","article-title":"Crystallographic analysis at 3.0-\u00c5 resolution\nof the binding to human thrombin of four active site-directed inhibitors","volume":"266","author":"Banner","year":"1991","journal-title":"J. Biol. Chem."},{"key":"2026090305371585700_cit68","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1021\/bi00296a014","article-title":"Selective inhibition\nof thrombin by (2R,4R)-4-methyl-1-[N2-[1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl]-2-piperidinecarboxylic\nacid","volume":"23","author":"Kikumoto","year":"1984","journal-title":"Biochemistry"},{"key":"2026090305371585700_cit69","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrd1466","article-title":"A new oral anticoagulant: the 50-year challenge","volume":"3","author":"Gustafsson","year":"2004","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026090305371585700_cit70","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpb.2016.12.027","article-title":"Quantitative\nanalysis of lab-to-lab variability in Caco-2 permeability assays","volume":"114","author":"Lee","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2026090305371585700_cit71","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","article-title":"The direct thrombin\ninhibitor melagatran and its oral prodrug H 376\/95: Intestinal absorption\nproperties, biochemical and pharmacodynamic effects","volume":"101","author":"Gustafsson","year":"2001","journal-title":"Thromb. Res."},{"key":"2026090305371585700_cit72","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1016\/S0006-3495(96)79479-1","article-title":"Crystal structures of thrombin with thiazole-containing\ninhibitors: probes of the S1\u2032 binding site","volume":"71","author":"Matthews","year":"1996","journal-title":"Biophys. J."},{"key":"2026090305371585700_cit73","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/jm0109513","article-title":"Structure-based design of novel potent\nnonpeptide thrombin inhibitors","volume":"45","author":"Hauel","year":"2002","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit74","doi-asserted-by":"publisher","first-page":"8511","DOI":"10.1002\/anie.200701169","article-title":"Thermodynamic inhibition profile of a cyclopentyl and a cyclohexyl\nderivative towards thrombin: the same but for different reasons","volume":"46","author":"Gerlach","year":"2007","journal-title":"Angew. Chem., Int. Ed."},{"key":"2026090305371585700_cit75","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0969-2126(96)00142-6","article-title":"Enzyme flexibility, solvent and \u2019weak\u2019\ninteractions characterize thrombin-ligand interactions: implications\nfor drug design","volume":"4","author":"Engh","year":"1996","journal-title":"Structure"},{"key":"2026090305371585700_cit76","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1016\/j.bmcl.2004.06.030","article-title":"Low molecular weight thrombin inhibitors\nwith excellent potency, metabolic stability, and oral bioavailability","volume":"14","author":"Morrissette","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305371585700_cit77","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1021\/jm901802n","article-title":"Discovery and clinical\nevaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone\n(RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif","volume":"53","author":"Lu","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit78","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1021\/jm030303e","article-title":"Discovery and evaluation of potent P1 aryl\nheterocycle-based thrombin inhibitors","volume":"47","author":"Young","year":"2004","journal-title":"J. Med.\nChem."},{"key":"2026090305371585700_cit79","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1039\/C5MD00479A","article-title":"Discovery of AZD8165 - a clinical candidate from a\nnovel series of neutral thrombin inhibitors","volume":"7","author":"Abrahamsson","year":"2016","journal-title":"MedChemComm"},{"key":"2026090305371585700_cit80","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1021\/jm9706933","article-title":"Design of novel,\npotent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures:\nRapid structure\u2013activity studies by solid-phase synthesis","volume":"41","author":"Lumma","year":"1998","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit81","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1161\/ATVBAHA.110.203604","article-title":"Dabigatran: An oral novel potent reversible nonpeptide\ninhibitor of thrombin","volume":"30","author":"Eisert","year":"2010","journal-title":"Arterioscler., Thromb.,\nVasc. Biol."},{"key":"2026090305371585700_cit82","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1124\/dmd.113.053561","article-title":"Impact of endogenous esterase activity\non in vitro P-glycoprotein profiling of dabigatran etexilate in Caco-2\nmonolayers","volume":"42","author":"Ishiguro","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"2026090305371585700_cit83","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04453.x","article-title":"Oral bioavailability of dabigatran\netexilate (Pradaxa((R))) after co-medication with verapamil in healthy\nsubjects","volume":"75","author":"Hartter","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2026090305371585700_cit84","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jmb.2009.04.051","article-title":"More than\na simple lipophilic contact: A detailed thermodynamic analysis of\nnonbasic residues in the S1 pocket of thrombin","volume":"390","author":"Baum","year":"2009","journal-title":"J. Mol. Biol."},{"key":"2026090305371585700_cit85","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1002\/anie.200806219","article-title":"Evidence for C-Cl\/C-Br\u00b7\u00b7\u00b7\u03c0\ninteractions as an important contribution to protein\u2013ligand\nbinding affinity","volume":"48","author":"Matter","year":"2009","journal-title":"Angew. Chem., Int. Ed."},{"key":"2026090305371585700_cit86","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1161\/01.ATV.0000228844.65168.d1","article-title":"Thrombin-cofactor\ninteractions: structural insights into regulatory mechanisms","volume":"26","author":"Adams","year":"2006","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"key":"2026090305371585700_cit87","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.beha.2004.02.002","article-title":"Bivalent direct thrombin inhibitors:\nhirudin and bivalirudin","volume":"17","author":"Warkentin","year":"2004","journal-title":"Best Pract. Res., Clin.\nHaematol."},{"key":"2026090305371585700_cit88","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/jth.13237","article-title":"Biosimilars of low-molecular-weight\nheparin products: fostering competition or reducing \u201cbiodiversity\u201d?","volume":"14","author":"Harenberg","year":"2016","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit89","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nsmb810","article-title":"The ternary complex\nof antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor\nspecificity","volume":"11","author":"Dementiev","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2026090305371585700_cit90","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.thromres.2014.05.021","article-title":"Development of aptamer\noligonucleotides as anticoagulants and antithrombotics for cardiovascular\ndiseases: Current status","volume":"134","author":"Li","year":"2014","journal-title":"Thromb. Res."},{"key":"2026090305371585700_cit91","unstructured":"https:\/\/www.enterprise.cam.ac.uk\/case-studies\/xo1-and-a-ground-breaking-drug-candidate\/ (accessed August 8, 2017)."},{"key":"2026090305371585700_cit92","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/jth.13203","article-title":"Challenging\nthe anticoagulant paradigm?","volume":"14","author":"Ten Cate","year":"2016","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit93","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1471-4892(01)00031-5","article-title":"The role\nof tissue factor\/factor VIIa in the pathophysiology of acute thrombotic\nformation","volume":"1","author":"Girard","year":"2001","journal-title":"Curr. Opin. Pharmacol."},{"key":"2026090305371585700_cit94","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/36862","article-title":"Mice lacking factor VII develop normally but suffer\nfatal perinatal bleeding","volume":"390","author":"Rosen","year":"1997","journal-title":"Nature"},{"key":"2026090305371585700_cit95","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1160\/TH05-05-0337","article-title":"Generation\nof genetically-altered mice producing very low levels of coagulation\nfactor VII","volume":"94","author":"Rosen","year":"2005","journal-title":"Thromb. Haemostasis"},{"key":"2026090305371585700_cit96","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/j.1365-2516.2008.01844.x","article-title":"Factor VII deficiency:\ndefining the clinical picture and optimizing therapeutic options","volume":"14","author":"Lapecorella","year":"2008","journal-title":"Haemophilia"},{"key":"2026090305371585700_cit97","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1538-7836.2003.t01-1-00553.x","article-title":"Rare Bleeding\nDisorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen\nand dysfibrinogenemias","volume":"2","author":"Acharya","year":"2004","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit98","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1098-1004(2001)17:1&lt;3::AID-HUMU2&gt;3.0.CO;2-V","article-title":"Factor VII deficiency and the FVII\nmutation database","volume":"17","author":"McVey","year":"2001","journal-title":"Hum. Mutat."},{"key":"2026090305371585700_cit99","first-page":"704","article-title":"Analysis of biological phenotypes from 42 patients\nwith inherited factor VII deficiency: Can biological tests predict\nthe bleeding risk?","volume":"89","author":"Giansily-Blaizot","year":"2004","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"2026090305371585700_cit100","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000217245","article-title":"Antithrombotic and antilesion benefits without hemorrhagic\nrisks by inhibiting tissue factor pathway","volume":"26","author":"Harker","year":"1996","journal-title":"Pathophysiol.\nHaemostasis Thromb."},{"key":"2026090305371585700_cit101","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-0037-1615608","article-title":"Inhibition of arterial thrombosis\nby a soluble tissue factor mutant and active site-blocked factors\nIXa and Xa in the guinea pig","volume":"85","author":"Himber","year":"2001","journal-title":"Thromb. Haemostasis"},{"key":"2026090305371585700_cit102","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.drudis.2014.05.023","article-title":"Tissue factor-fVIIa inhibition: update\non an unfinished quest for a novel oral antithrombotic","volume":"19","author":"Priestley","year":"2014","journal-title":"Drug Discovery Today"},{"key":"2026090305371585700_cit103","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.bmcl.2005.12.059","article-title":"Factor VIIa inhibitors: chemical\noptimization, preclinical pharmacokinetics, pharmacodynamics, and\nefficacy in an arterial baboon thrombosis model","volume":"16","author":"Young","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305371585700_cit104","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1016\/j.bmcl.2013.02.013","article-title":"Discovery\nand gram-scale synthesis of BMS-593214, a potent, selective FVIIa\ninhibitor","volume":"23","author":"Priestley","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305371585700_cit105","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.bbrc.2004.11.108","article-title":"Novel interactions of large P3 moiety\nand small P4 moiety in the binding of the peptide mimetic factor VIIa\ninhibitor","volume":"326","author":"Kadono","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2026090305371585700_cit106","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1021\/acs.jmedchem.6b00244","article-title":"Atropisomer\ncontrol in macrocyclic factor VIIa inhibitors","volume":"59","author":"Glunz","year":"2016","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit107","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/380041a0","article-title":"The crystal structure of the complex\nof blood coagulation factor VIIa with soluble tissue factor","volume":"380","author":"Banner","year":"1996","journal-title":"Nature"},{"key":"2026090305371585700_cit108","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3998\/ark.5550190.0006.507","article-title":"Acid-base interactions in some isoquinoline and quinazoline\namino derivatives","author":"Zielinski","year":"2005","journal-title":"ARKIVOC"},{"key":"2026090305371585700_cit109","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1021\/acsmedchemlett.6b00375","article-title":"Design\nand synthesis of novel meta-linked phenylglycine macrocyclic FVIIa\ninhibitors","volume":"8","author":"Richter","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"2026090305371585700_cit110","doi-asserted-by":"publisher","first-page":"7125","DOI":"10.1021\/acs.jmedchem.6b00469","article-title":"Discovery\nof a highly potent, selective, and orally bioavailable macrocyclic\ninhibitor of blood coagulation factor VIIa-tissue factor complex","volume":"59","author":"Zhang","year":"2016","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit111","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1016\/j.bmcl.2016.08.088","article-title":"Synthesis and P1\u2032 SAR exploration\nof potent macrocyclic tissue factor-factor VIIa inhibitors","volume":"26","author":"Ladziata","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305371585700_cit112","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2005-09-3879","article-title":"Bleeding in carriers of hemophilia","volume":"108","author":"Plug","year":"2006","journal-title":"Blood"},{"key":"2026090305371585700_cit113","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1161\/ATVBAHA.110.203117","article-title":"Coagulation factor\nIXa as a target for treatment and prophylaxis of venous thromboembolism","volume":"30","author":"Eikelboom","year":"2010","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"key":"2026090305371585700_cit114","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0140-6736(03)14021-4","article-title":"Decreased\nmortality of ischaemic heart disease among carriers of haemophilia","volume":"362","author":"Sramek","year":"2003","journal-title":"Lancet"},{"key":"2026090305371585700_cit115","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/blood-2006-10-050435","article-title":"Mortality rates, life expectancy, and causes of death\nin people with hemophilia A or B in the United Kingdom who were not\ninfected with HIV","volume":"110","author":"Darby","year":"2007","journal-title":"Blood"},{"key":"2026090305371585700_cit116","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1160\/TH08-04-0262","article-title":"Factor IX: insights from knock-out\nand genetically engineered mice","volume":"100","author":"Monahan","year":"2008","journal-title":"Thromb. Haemostasis"},{"key":"2026090305371585700_cit117","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of\nfactor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl.\nJ. Med."},{"key":"2026090305371585700_cit118","doi-asserted-by":"publisher","first-page":"e00207","DOI":"10.1002\/prp2.207","article-title":"Preclinical and translational\nevaluation of coagulation factor IXa as a novel therapeutic target","volume":"4","author":"Ankrom","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"2026090305371585700_cit119","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1538-7836.2007.02872.x","article-title":"Partial factor IXa inhibition with\nTTP889 for prevention of venous thromboembolism: an exploratory study","volume":"6","author":"Eriksson","year":"2008","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit120","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S0969-2126(99)80125-7","article-title":"Coagulation factor\nIXa: the relaxed conformation of Tyr99 blocks substrate binding","volume":"7","author":"Hopfner","year":"1999","journal-title":"Structure"},{"key":"2026090305371585700_cit121","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1021\/jm901476x","article-title":"Structure based drug design: development of potent\nand selective factor IXa (FIXa) inhibitors","volume":"53","author":"Wang","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit122","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1016\/j.bmcl.2004.08.034","article-title":"SAR and\nfactor IXa crystal structure of a dual inhibitor of factors IXa and\nXa","volume":"14","author":"Smallheer","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305371585700_cit123","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1016\/j.bmcl.2015.07.078","article-title":"Development of a\nnovel tricyclic class of potent and selective FIXa inhibitors","volume":"25","author":"Meng","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305371585700_cit124","doi-asserted-by":"publisher","first-page":"d1915","DOI":"10.2741\/A888","article-title":"Gene targeting in hemostasis. Factor\nX","volume":"7","author":"Rosen","year":"2002","journal-title":"Front. Biosci., Landmark Ed."},{"key":"2026090305371585700_cit125","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1538-7836.2007.02849.x","article-title":"A viable mouse model of factor X deficiency provides\nevidence for maternal transfer of factor X","volume":"6","author":"Tai","year":"2008","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit126","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/j.1365-2516.2008.01856.x","article-title":"Diagnosis and treatment\nof inherited factor X deficiency","volume":"14","author":"Brown","year":"2008","journal-title":"Haemophilia"},{"key":"2026090305371585700_cit127","doi-asserted-by":"publisher","first-page":"141S","DOI":"10.1378\/chest.08-0689","article-title":"Parenteral Anticoagulants:\nAmerican College of Chest Physicians Evidence-Based Clinical Practice\nGuidelines (8th Edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"key":"2026090305371585700_cit128","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1093\/eurheartj\/sun003","article-title":"Selective factor Xa inhibition with\nfondaparinux: from concept to clinical benefit","volume":"10","author":"Turpie","year":"2008","journal-title":"Eur. Heart J. Suppl."},{"key":"2026090305371585700_cit129","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1021\/jm100146h","article-title":"Factor Xa inhibitors: Next-generation antithrombotic\nagents","volume":"53","author":"Pinto","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit130","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1021\/jm050101d","article-title":"Discovery of the novel antithrombotic\nagent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-\n2-carboxamide (BAY 59-7939): An oral, direct factor Xa inhibitor","volume":"48","author":"Roehrig","year":"2005","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit131","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the\nnovel antithrombotic agent BAY 59\u20137939 -an oral, direct factor\nXa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit132","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics\nof BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple\ndosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur. J. Clin.\nPharmacol."},{"key":"2026090305371585700_cit133","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s40265-014-0278-5","article-title":"Clinical use of rivaroxaban: Pharmacokinetic and pharmacodynamic\nrationale for dosing regimens in different indications","volume":"74","author":"Trujillo","year":"2014","journal-title":"Drugs"},{"key":"2026090305371585700_cit134","first-page":"206","article-title":"Role of apixaban (Eliquis) in the\ntreatment and prevention of thromboembolic disease","volume":"38","author":"Budovich","year":"2013","journal-title":"Pharm. Ther."},{"key":"2026090305371585700_cit135","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00277-015-2566-x","article-title":"How to choose appropriate direct\noral anticoagulant for patient with nonvalvular atrial fibrillation","volume":"95","author":"Schaefer","year":"2016","journal-title":"Ann. Hematol."},{"key":"2026090305371585700_cit136","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1021\/jm070245n","article-title":"Discovery of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl]phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide\n(apixaban, BMS-562247), a highly potent, selective, efficacious, and\norally bioavailable inhibitor of blood coagulation factor Xa","volume":"50","author":"Pinto","year":"2007","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit137","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","article-title":"DU-176b, a potent and orally active factor Xa inhibitor:\nin vitro and in vivo pharmacological profiles","volume":"6","author":"Furugohri","year":"2008","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit138","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.bmcl.2009.02.111","article-title":"Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a\nhighly potent, selective, and orally efficacious factor Xa inhibitor","volume":"19","author":"Zhang","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305371585700_cit139","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1021\/jm901699j","article-title":"Discovery of a tetrahydropyrimidin-2(1H)-one derivative\n(TAK-442) as a potent, selective, and orally active factor Xa inhibitor","volume":"53","author":"Fujimoto","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit140","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1021\/jm200868m","article-title":"Discovery\nof N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide\n(darexaban, YM150) as a potent and orally available factor Xa inhibitor","volume":"54","author":"Hirayama","year":"2011","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit141","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1747-0285.2007.00539.x","article-title":"The discovery of (2R,4R)-N-(4-chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-\nmethoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious\nfactor Xa inhibitor","volume":"70","author":"Kohrt","year":"2007","journal-title":"Chem. Biol. Drug Des."},{"key":"2026090305371585700_cit142","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.2174\/092986707782023659","article-title":"The discovery of\nthe factor Xa inhibitor otamixaban: from lead identification to clinical\ndevelopment","volume":"14","author":"Guertin","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"2026090305371585700_cit143","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.1021\/jm030212h","article-title":"Discovery\nof 1-(2-aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-2\u2032-(aminosulfonyl)[1,1\u2032-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective,\nand orally bioavailable factor Xa inhibitor","volume":"46","author":"Pruitt","year":"2003","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit144","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended thromboprophylaxis\nwith betrixaban in acutely ill medical patients","volume":"375","author":"Cohen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2026090305371585700_cit145","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","article-title":"RUBY-1: a randomized, double-blind,\nplacebo-controlled trial of the safety and tolerability of the novel\noral factor Xa inhibitor darexaban (YM150) following acute coronary\nsyndrome","volume":"32","author":"Steg","year":"2011","journal-title":"Eur. Heart J."},{"key":"2026090305371585700_cit146","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/j.1365-2516.2008.01667.x","article-title":"Factor XI\ndeficiency","volume":"14","author":"Gomez","year":"2008","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"2026090305371585700_cit147","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1538-7836.2009.03393.x","article-title":"Factor\nXI deficiency in animal models","volume":"7","author":"Renne","year":"2009","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit148","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/MOH.0b013e3283497e61","article-title":"Factor XI and XII as antithrombotic\ntargets","volume":"18","author":"Muller","year":"2011","journal-title":"Curr. Opin. Hematol."},{"key":"2026090305371585700_cit149","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2011-10-387134","article-title":"Antisense\ninhibition of coagulation factor XI prolongs APTT without increased\nbleeding risk in cynomolgus monkeys","volume":"119","author":"Younis","year":"2012","journal-title":"Blood"},{"key":"2026090305371585700_cit150","unstructured":"http:\/\/pharma.bayer.com\/en\/innovation-partnering\/development-pipeline\/ (accessed October 10, 2017)."},{"key":"2026090305371585700_cit151","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Investigators,\nF.-A. T. Factor XI antisense oligonucleotide for prevention of venous\nthrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2026090305371585700_cit152","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1517\/13543776.2016.1154045","article-title":"Factor XIa inhibitors:\nA review of the patent literature","volume":"26","author":"Al-Horani","year":"2016","journal-title":"Expert Opin.\nTher. Pat."},{"key":"2026090305371585700_cit153","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.bmcl.2015.01.028","article-title":"Structure-based\ndesign of inhibitors of coagulation factor XIa with novel P1 moieties","volume":"25","author":"Pinto","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305371585700_cit154","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1021\/acs.jmedchem.6b01460","article-title":"Structure-based\ndesign of macrocyclic factor XIa inhibitors: Discovery of the macrocyclic\namide linker","volume":"60","author":"Corte","year":"2017","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit155","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1016\/S0960-894X(02)00688-1","article-title":"Synthesis\nand SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors","volume":"12","author":"Sutton","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305371585700_cit156","doi-asserted-by":"publisher","first-page":"7989","DOI":"10.1021\/bi990098y","article-title":"Mechanistic\ninsights into the inhibition of serine proteases by monocyclic lactams","volume":"38","author":"Wilmouth","year":"1999","journal-title":"Biochemistry"},{"key":"2026090305371585700_cit157","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.bmcl.2006.02.052","article-title":"Synthesis,\nSAR exploration, and X-ray crystal structures of factor XIa inhibitors\ncontaining an \u03b1-ketothiazole arginine","volume":"16","author":"Deng","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305371585700_cit158","doi-asserted-by":"publisher","first-page":"e0113705","DOI":"10.1371\/journal.pone.0113705","article-title":"Creating novel activated factor XI inhibitors through\nfragment based lead generation and structure aided drug design","volume":"10","author":"Fjellstro\u0308m","year":"2015","journal-title":"PLoS One"},{"key":"2026090305371585700_cit159","unstructured":"Chrusciel, R. A.; Gadwood, R. C.; Hayward, N. J.; Melnick, M. J.; Navia, M.; Poel, T. J.; Stewart, C. A.; Stassen, F. L.\n          Preparation\nof \u03b2-Lactam Derivatives as Inhibitors of Factor Xia or Kallikrein. PCT Int. Pat. Appl. Publ. WO2015120062, 2015; Exithera\nPharmaceuticals Inc., U.S."},{"key":"2026090305371585700_cit160","doi-asserted-by":"crossref","first-page":"13666","DOI":"10.1016\/S0021-9258(17)38776-8","article-title":"Characterization\nof human blood coagulation factor XII cDNA. Prediction of the primary\nstructure of factor XII and the tertiary structure of beta-factor\nXIIa","volume":"260","author":"Cool","year":"1985","journal-title":"J. Biol. Chem."},{"key":"2026090305371585700_cit161","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1182\/blood-2016-10-744110","article-title":"Proteolytic properties of single-chain\nfactor XII: a mechanism for triggering contact activation","volume":"129","author":"Ivanov","year":"2017","journal-title":"Blood"},{"key":"2026090305371585700_cit162","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/jth.13235","article-title":"Contact system revisited: an interface between inflammation, coagulation,\nand innate immunity","volume":"14","author":"Long","year":"2016","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit163","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1182\/blood-2012-07-292094","article-title":"In vivo roles of factor XII","volume":"120","author":"Renne","year":"2012","journal-title":"Blood"},{"key":"2026090305371585700_cit164","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1084\/jem.20052458","article-title":"Targeting coagulation factor XII\nprovides protection from pathological thrombosis in cerebral ischemia\nwithout interfering with hemostasis","volume":"203","author":"Kleinschnitz","year":"2006","journal-title":"J. Exp.\nMed."},{"key":"2026090305371585700_cit165","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1016\/j.neuroimage.2009.11.061","article-title":"Enhanced cortical reperfusion protects\ncoagulation factor XII-deficient mice from ischemic stroke as revealed\nby high-field MRI","volume":"49","author":"Pham","year":"2010","journal-title":"NeuroImage"},{"key":"2026090305371585700_cit166","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","article-title":"Factor XII inhibition\nreduces thrombus formation in a primate thrombosis model","volume":"123","author":"Matafonov","year":"2014","journal-title":"Blood"},{"key":"2026090305371585700_cit167","doi-asserted-by":"publisher","first-page":"222ra17","DOI":"10.1126\/scitranslmed.3006804","article-title":"A factor XIIa inhibitory antibody\nprovides thromboprotection in extracorporeal circulation without increasing\nbleeding risk","volume":"6","author":"Larsson","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2026090305371585700_cit168","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3978\/j.issn.2305-5839.2015.09.07","article-title":"The factor XIIa blocking antibody\n3F7: a safe anticoagulant with anti-inflammatory activities","volume":"3","author":"Worm","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"2026090305371585700_cit169","doi-asserted-by":"publisher","first-page":"e0146783","DOI":"10.1371\/journal.pone.0146783","article-title":"The coagulation factor XIIa inhibitor rHA-infestin-4\nimproves outcome after cerebral ischemia\/reperfusion injury in rats","volume":"11","author":"Krupka","year":"2016","journal-title":"PLoS One"},{"key":"2026090305371585700_cit170","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/jth.13209","article-title":"The Alzheimer\u2019s disease peptide\nA\u03b2 promotes thrombin generation through activation of coagulation\nfactor XII","volume":"14","author":"Zamolodchikov","year":"2016","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit171","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1073\/pnas.1423764112","article-title":"Activation of the factor XII-driven\ncontact system in Alzheimer\u2019s disease patient and mouse model\nplasma","volume":"112","author":"Zamolodchikov","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090305371585700_cit172","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/S0049-3848(16)30367-X","article-title":"A possible\nnew role for A\u03b2 in vascular and inflammatory dysfunction in\nAlzheimer\u2019s disease","volume":"141","author":"Zamolodchikov","year":"2016","journal-title":"Thromb. Res."},{"key":"2026090305371585700_cit173","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1182\/blood-2016-11-753202","article-title":"Depletion\nof coagulation factor XII ameliorates brain pathology and cognitive\nimpairment in Alzheimer disease mice","volume":"129","author":"Chen","year":"2017","journal-title":"Blood"},{"key":"2026090305371585700_cit174","unstructured":"Factor XIIa 1536 HTS Dose Response Confirmation. PubChem\nAID 852. https:\/\/pubchem.ncbi.nlm.nih.gov\/bioassay\/852 (accessed August\n8, 2017)."},{"key":"2026090305371585700_cit175","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejmech.2016.01.023","article-title":"Synthesis, evaluation and structure-activity\nrelationship of new 3-carboxamide coumarins as FXIIa inhibitors","volume":"110","author":"Bouckaert","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"2026090305371585700_cit176","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1021\/acs.jmedchem.6b01548","article-title":"Peptide macrocycle\ninhibitor of coagulation factor XII with subnanomolar affinity and\nhigh target selectivity","volume":"60","author":"Middendorp","year":"2017","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit177","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1021\/acschembio.5b00103","article-title":"A synthetic factor XIIa inhibitor blocks selectively\nintrinsic coagulation initiation","volume":"10","author":"Baeriswyl","year":"2015","journal-title":"ACS Chem.\nBiol."},{"key":"2026090305371585700_cit178","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1021\/jm400236j","article-title":"Development of a selective peptide macrocycle inhibitor\nof coagulation factor XII toward the generation of a safe antithrombotic\ntherapy","volume":"56","author":"Baeriswyl","year":"2013","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit179","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/jth.12849","article-title":"Coagulation factor XII protease domain crystal structure","volume":"13","author":"Pathak","year":"2015","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit180","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jmb.2004.12.048","article-title":"Conformational\nlability in serine protease active sites: Structures of hepatocyte\ngrowth factor activator (HGFA) alone and with the inhibitory domain\nfrom HGFA inhibitor-1B","volume":"346","author":"Shia","year":"2005","journal-title":"J. Mol. Biol."},{"key":"2026090305371585700_cit181","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1021\/jm960668h","article-title":"Synthesis and structure-activity\nrelationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine","volume":"40","author":"Sturzebecher","year":"1997","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit182","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1160\/TH12-11-0840","article-title":"Structure of plasma\nand tissue kallikreins","volume":"110","author":"Pathak","year":"2013","journal-title":"Thromb. Haemostasis"},{"key":"2026090305371585700_cit183","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nrd4534","article-title":"Unleashing the therapeutic potential of human kallikrein-related\nserine proteases","volume":"14","author":"Prassas","year":"2015","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026090305371585700_cit184","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1084\/jem.147.3.719","article-title":"Surface and fluid phase activities of two forms of\nactivated Hageman factor produced during contact activation of plasma","volume":"147","author":"Revak","year":"1978","journal-title":"J. Exp. Med."},{"key":"2026090305371585700_cit185","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2174\/1566524014666141015153519","article-title":"Prolylcarboxypeptidase\nindependently activates plasma prekallikrein (Fletcher Factor)","volume":"14","author":"Wang","year":"2014","journal-title":"Curr. Mol. Med."},{"key":"2026090305371585700_cit186","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/CRD.0000000000000069","article-title":"Plasma kallikrein\ninhibitors in cardiovascular disease: An innovative therapeutic approach","volume":"24","author":"Kolte","year":"2016","journal-title":"Cardiol. Rev."},{"key":"2026090305371585700_cit187","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1586\/ehm.10.69","article-title":"Congenital\nprekallikrein deficiency","volume":"3","author":"Girolami","year":"2010","journal-title":"Expert Rev. Hematol."},{"key":"2026090305371585700_cit188","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1160\/TH11-10-0682","article-title":"Effects of\nplasma kallikrein deficiency on haemostasis and thrombosis in mice:\nmurine ortholog of the Fletcher trait","volume":"107","author":"Bird","year":"2012","journal-title":"Thromb.\nHaemostasis"},{"key":"2026090305371585700_cit189","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/cmdc.201200071","article-title":"Bicyclic peptides with optimized ring size inhibit\nhuman plasma kallikrein and its orthologues while sparing paralogous\nproteases","volume":"7","author":"Baeriswyl","year":"2012","journal-title":"ChemMedChem"},{"key":"2026090305371585700_cit190","doi-asserted-by":"publisher","first-page":"e115872","DOI":"10.1371\/journal.pone.0115872","article-title":"A cyclic\npeptidic serine protease inhibitor: increasing affinity by increasing\npeptide flexibility","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"2026090305371585700_cit191","doi-asserted-by":"publisher","first-page":"41077","DOI":"10.1074\/jbc.M506766200","article-title":"Expression, crystallization,\nand three-dimensional structure of the catalytic domain of human plasma\nkallikrein","volume":"280","author":"Tang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2026090305371585700_cit192","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/0049-3848(89)90301-0","article-title":"A new assay for the determination of factor XII in\nplasma using a chromogenic substrate and a selective inhibitor of\nplasma kallikrein","volume":"55","author":"Sturzebecher","year":"1989","journal-title":"Thromb. Res."},{"key":"2026090305371585700_cit193","unstructured":"Van de Locht, A.; Dietrich, W.; Englberger, L.; Villiger, P.; Villiger, J.\n          Methods of Treating or Preventing Blood Loss During\nSurgery Using the Serine Protease Inhibitor MDCO-2010. PCT Int. Pat. Appl. Publ. WO2013052736, 2013; The Medicines\nCompany, U.S."},{"key":"2026090305371585700_cit194","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2174\/187152512800388939","article-title":"PF-04886847 (an inhibitor of plasma\nkallikrein) attenuates inflammatory mediators and activation of blood\ncoagulation in rat model of lipopolysaccharide (LPS)-induced sepsis","volume":"10","author":"Kolte","year":"2012","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"2026090305371585700_cit195","first-page":"479","article-title":"Biochemistry and applications\nof aprotinin, the kallikrein inhibitor from bovine organs","volume":"33","author":"Fritz","year":"1983","journal-title":"Arzneim. Forsch."},{"key":"2026090305371585700_cit196","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/bja\/aet008","article-title":"III. Aprotinin and cardiac surgery: a sorry tale of\nevidence misused","volume":"110","author":"McMullan","year":"2013","journal-title":"Br. J. Anaesth."},{"key":"2026090305371585700_cit197","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1358\/dot.2010.46.8.1507205","article-title":"Ecallantide: a plasma\nkallikrein inhibitor for the treatment of acute attacks of hereditary\nangioedema","volume":"46","author":"Stolz","year":"2010","journal-title":"Drugs Today"},{"key":"2026090305371585700_cit198","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jtcvs.2011.06.001","article-title":"A phase 2 prospective, randomized,\ndouble-blind trial comparing the effects of tranexamic acid with ecallantide\non blood loss from high-risk cardiac surgery with cardiopulmonary\nbypass (CONSERV-2 Trial)","volume":"143","author":"Bokesch","year":"2012","journal-title":"J. Thorac. Cardiovasc.\nSurg."},{"key":"2026090305371585700_cit199","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1213\/ANE.0000000000000218","article-title":"A novel blood-sparing agent in cardiac surgery? First\nin-patient experience with the synthetic serine protease inhibitor\nMDCO-2010: a phase II, randomized, double-blind, placebo-controlled\nstudy in patients undergoing coronary artery bypass grafting with\ncardiopulmonary bypass","volume":"119","author":"Englberger","year":"2014","journal-title":"Anesth. Analg."},{"key":"2026090305371585700_cit200","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1213\/ANE.0000000000000225","article-title":"Development of a\nnovel blood-sparing agent in cardiac surgery: do we need another agent?","volume":"119","author":"Faraoni","year":"2014","journal-title":"Anesth. Analg."},{"key":"2026090305371585700_cit201","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/ALN.0b013e318191408c","article-title":"CU-2010-A novel small molecule protease\ninhibitor with antifibrinolytic and anticoagulant properties","volume":"110","author":"Dietrich","year":"2009","journal-title":"Anesthesiology"},{"key":"2026090305371585700_cit202","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s00125-016-3974-8","article-title":"Diabetic macular\noedema: pathophysiology, management challenges and treatment resistance","volume":"59","author":"Bahrami","year":"2016","journal-title":"Diabetologia"},{"key":"2026090305371585700_cit203","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.2337\/db15-0317","article-title":"Plasma kallikrein-kinin system as\na VEGF-independent mediator of diabetic macular edema","volume":"64","author":"Kita","year":"2015","journal-title":"Diabetes"},{"key":"2026090305371585700_cit204","unstructured":"http:\/\/www.kalvista.com\/assets\/docs\/press\/11_KVP_01%20Series%20A%20Final1.pdf (accessed August 8, 2017)."},{"key":"2026090305371585700_cit205","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1167\/iovs.15-18272","article-title":"Plasma\nkallikrein mediates vascular endothelial growth factor-induced retinal\ndysfunction and thickening","volume":"57","author":"Clermont","year":"2016","journal-title":"Invest. Ophthalmol.\nVisual Sci."},{"key":"2026090305371585700_cit206","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","article-title":"Molecular mechanisms of fibrinolysis","volume":"129","author":"Cesarman-Maus","year":"2005","journal-title":"Br. J. Haematol."},{"key":"2026090305371585700_cit207","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1055\/s-0034-1398383","article-title":"Hemostatic and thrombotic issues\nin cardiac surgery","volume":"41","author":"Ranucci","year":"2015","journal-title":"Semin. Thromb. Hemostasis"},{"key":"2026090305371585700_cit208","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/med.21315","article-title":"Recent advances\non plasmin inhibitors for the treatment of fibrinolysis-related disorders","volume":"34","author":"Al-Horani","year":"2014","journal-title":"Med. Res. Rev."},{"key":"2026090305371585700_cit209","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/2359","article-title":"The ternary\nmicroplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate\ncomplex in action","volume":"5","author":"Parry","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"2026090305371585700_cit210","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1021\/jm3012917","article-title":"Development of new cyclic plasmin\ninhibitors with excellent potency and selectivity","volume":"56","author":"Saupe","year":"2013","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit211","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.bbrc.2011.08.102","article-title":"Identification of\nthe site of binding of sulfated, low molecular weight lignins on thrombin","volume":"413","author":"Abdel Aziz","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2026090305371585700_cit212","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1021\/acs.jmedchem.6b01474","article-title":"Potent, selective, allosteric inhibition\nof human plasmin by sulfated non-saccharide glycosaminoglycan mimetics","volume":"60","author":"Afosah","year":"2017","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit213","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/2359","article-title":"The ternary\nmicroplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate\ncomplex in action","volume":"5","author":"Parry","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"2026090305371585700_cit214","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1365-2516.2007.01562.x","article-title":"Recommendations for reporting economic evaluations\nof haemophilia prophylaxis: a nominal groups consensus statement on\nbehalf of the Economics Expert Working Group of The International\nProphylaxis Study Group","volume":"14","author":"Nicholson","year":"2008","journal-title":"Haemophilia"},{"key":"2026090305371585700_cit215","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1164\/ajrccm.158.5.9712022","article-title":"Hereditary thrombophilia and venous thromboembolism","volume":"158","author":"Murin","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026090305371585700_cit216","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1111\/j.1538-7836.2011.04504.x","article-title":"Activated protein C inhibitor for correction of thrombin\ngeneration in hemophilia A blood and plasma1","volume":"9","author":"Brummel-Ziedins","year":"2011","journal-title":"J. Thromb. Haemostasis"},{"key":"2026090305371585700_cit217","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1111\/j.1538-7836.2006.02226.x","article-title":"Peptidomimetic inhibitors for activated protein C:\nimplications for hemophilia management","volume":"4","author":"Butenas","year":"2006","journal-title":"J. Thromb.\nHaemostasis"},{"key":"2026090305371585700_cit218","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1021\/jm0606950","article-title":"Low molecular\nweight activated protein C inhibitors as a potential treatment for\nhemophilic disorders","volume":"49","author":"De Nanteuil","year":"2006","journal-title":"J. Med. Chem."},{"key":"2026090305371585700_cit219","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.bmcl.2013.12.094","article-title":"Design, synthesis,\nand SAR of a series of activated protein C (APC) inhibitors with selectivity\nagainst thrombin for the treatment of haemophilia","volume":"24","author":"Bach","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305371585700_cit220","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.thromres.2014.01.026","article-title":"Identification of novel small molecule inhibitors of\nactivated protein C","volume":"133","author":"Sperandio","year":"2014","journal-title":"Thromb. Res."},{"key":"2026090305371585700_cit221","doi-asserted-by":"crossref","first-page":"6822","DOI":"10.1002\/j.1460-2075.1996.tb01073.x","article-title":"The 2.8 A\ncrystal structure of Gla-domainless activated protein C","volume":"15","author":"Mather","year":"1996","journal-title":"EMBO J."},{"key":"2026090305371585700_cit222","doi-asserted-by":"publisher","first-page":"e0140713","DOI":"10.1371\/journal.pone.0140713","article-title":"Dynamics govern specificity of a\nprotein-protein interface: Substrate recognition by thrombin","volume":"10","author":"Fuchs","year":"2015","journal-title":"PLoS One"},{"key":"2026090305371585700_cit223","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1074\/mcp.M500004-MCP200","article-title":"High throughput\nsubstrate specificity profiling of serine and cysteine proteases using\nsolution-phase fluorogenic peptide microarrays","volume":"4","author":"Gosalia","year":"2005","journal-title":"Mol. Cell. Proteomics"},{"key":"2026090305371585700_cit224","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s11239-015-1288-1","article-title":"Universal, class-specific and drug-specific reversal\nagents for the new oral anticoagulants","volume":"41","author":"Ansell","year":"2016","journal-title":"J. Thromb.\nThrombolysis"},{"key":"2026090305371585700_cit225","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/VHRM.S89130","article-title":"Reversing anticoagulant effects of novel oral anticoagulants:\nrole of ciraparantag, andexanet alfa, and idarucizumab","volume":"12","author":"Hu","year":"2016","journal-title":"Vasc. Health Risk Manage."},{"key":"2026090305371585700_cit226","doi-asserted-by":"publisher","first-page":"264","DOI":"10.5811\/westjem.2016.3.29294","article-title":"Anticoagulation reversal and treatment\nstrategies in major bleeding: Update 2016","volume":"17","author":"Christos","year":"2016","journal-title":"West.\nJ. Emerg. Med."},{"key":"2026090305371585700_cit227","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab\nfor dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2026090305371585700_cit228","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and\nindirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat. Med."},{"key":"2026090305371585700_cit229","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for\nacute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2026090305371585700_cit230","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0022-2836(84)90309-7","article-title":"Analysis of\nmembrane and surface protein sequences with the hydrophobic moment\nplot","volume":"179","author":"Eisenberg","year":"1984","journal-title":"J. Mol. Biol."},{"key":"2026090305371585700_cit231","doi-asserted-by":"publisher","first-page":"10037","DOI":"10.1073\/pnas.181342398","article-title":"Electrostatics of nanosystems: Application\nto microtubules and the ribosome","volume":"98","author":"Baker","year":"2001","journal-title":"Proc. Natl.\nAcad. Sci. U. S. A."},{"key":"2026090305371585700_cit232","doi-asserted-by":"publisher","first-page":"24873","DOI":"10.1074\/jbc.M509971200","article-title":"High resolution structures of p-aminobenzamidine-\nand benzamidine-VIIa\/soluble tissue factor: unpredicted conformation\nof the 192\u2013193 peptide bond and mapping of Ca2+,\nMg2+, Na+, and Zn2+ sites in factor\nVIIa","volume":"281","author":"Bajaj","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2026090305371585700_cit233","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1021\/acsmedchemlett.6b00384","article-title":"Structure-guided design of novel, potent, and selective macrocyclic\nplasma kallikrein inhibitors","volume":"8","author":"Li","year":"2017","journal-title":"ACS Med. Chem.\nLett."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.7b00772","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/61\/9\/3799\/67200287\/acs.jmedchem.7b00772.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/61\/9\/3799\/67200287\/acs.jmedchem.7b00772.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:37:26Z","timestamp":1788428246000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/61\/9\/3799\/764766\/Design-of-Small-Molecule-Active-Site-Inhibitors-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":233,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,10,26]]},"published-print":{"date-parts":[[2018,5,10]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00772","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]}}}